Add this topic to your myFT Digest for news straight to your inbox
Chief financial officer of world’s largest biotech company cautions on high valuations
Additional costs related to Hurricane Maria weigh on result
January M&A surge prompts questions over valuations
Drugmaker’s shares plunge on fears osteoporosis medication will not win approval
Pledge aims to convince insurers to pay for $14,000-a-year medicine
French drugmaker faces questions over how to offset declining Lantus revenues
Judge says Praluent infringes on patents held by Amgen covering rival treatment
Makers of medicines with $22bn sales a year expected to fight hard to delay rivals’ introduction
Trial of Repatha indicates it has fewer side effects than usual medication
Belgian group discovers bone-rebuilding treatment in South Africa
Chinese tech group starts ball rolling as US companies instruct banks after slow start to the year
Cautious sentiment risks cutting off funding for smaller biotechs
GSK, Amgen and Celgene among groups teaming up for Cancer Moonshot 2020 to trial experimental drugs
Pharma has seen a vigorous period of dealmaking
Companies with drugs already in clinical testing are being evaluated
Companies recently approved for new cholesterol drugs climb
International Edition